Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359923 | 0.73 | ALDH1A1 (0.35) | KDM4EALDH1A1 | |
| SCHEMBL5360360 | 0.70 | PSIP1 (0.38) | KDM4EALDH1A1 | |
| SCHEMBL5353125 | 0.64 | — | — | |
| SCHEMBL5358925 | 0.63 | — | — | |
| SCHEMBL5354802 | 0.63 | PDPK1 (0.32) | — | |
| SCHEMBL9900356 | 0.59 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL5361762 | 0.59 | AR (0.36) | ALDH1A1 | |
| SCHEMBL10094130 | 0.59 | BLM (0.45) | KAT2BKDM4EALDH1A1 | |
| SCHEMBL30196255 | 0.59 | TIPARP (0.46) | — | |
| SCHEMBL9900723 | 0.57 | TRPM8 (0.33) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553096-B1 | PYRAZOLE COMPOUNDS | UBE INDUSTRIES (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-7294625-B2 | Pyrazole compounds | UBE INDUSTRIES, LTD. (JP) | 2007-11-13 | — | — | US | disclosed |
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | UBE INDUSTRIES, LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1553096-A1 | PYRAZOLE COMPOUNDS | Ube Industries, Ltd. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | CNKSR1, MAPK1, MAPK3 | KAT2B 1338/4885KDM4E 1462/4885ALDH1A1 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.